A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
AUTHORS
Mark J. Levis / Alexander E. Perl / Jessica K. Altman / Christopher D. Gocke / Erkut Bahceci / Jason Hill / Chaofeng Liu / Zhiyi Xie / Andrew R. Carson / Valerie McClain / Timothy T. Stenzel / Jeffrey E. Miller
